487 related articles for article (PubMed ID: 11334404)
21. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
23. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.
Yang L; An HX; Deng XL; Chen LL; Li ZY
Acta Pharmacol Sin; 2003 May; 24(5):429-34. PubMed ID: 12740178
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
27. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat.
Pick A; Clark J; Kubstrup C; Levisetti M; Pugh W; Bonner-Weir S; Polonsky KS
Diabetes; 1998 Mar; 47(3):358-64. PubMed ID: 9519740
[TBL] [Abstract][Full Text] [Related]
28. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats.
Maier VH; Melvin DR; Lister CA; Chapman H; Gould GW; Murphy GJ
Diabetes; 2000 Apr; 49(4):618-25. PubMed ID: 10871200
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Sidell RJ; Cole MA; Draper NJ; Desrois M; Buckingham RE; Clarke K
Diabetes; 2002 Apr; 51(4):1110-7. PubMed ID: 11916933
[TBL] [Abstract][Full Text] [Related]
30. Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure.
Goh TT; Mason TM; Gupta N; So A; Lam TK; Lam L; Lewis GF; Mari A; Giacca A
Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E549-60. PubMed ID: 17003242
[TBL] [Abstract][Full Text] [Related]
31. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Pickavance LC; Buckingham RE; Wilding JP
Diabetes Obes Metab; 2001 Jun; 3(3):171-80. PubMed ID: 11412281
[TBL] [Abstract][Full Text] [Related]
32. Changes in islet capillary angioarchitecture coincide with impaired B-cell function but not with insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the diabetic phenotype at an advanced age.
Mizuno A; Noma Y; Kuwajima M; Murakami T; Zhu M; Shima K
Metabolism; 1999 Apr; 48(4):477-83. PubMed ID: 10206441
[TBL] [Abstract][Full Text] [Related]
33. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
[TBL] [Abstract][Full Text] [Related]
34. Thermal, but not mechanical, nociceptive behavior is altered in the Zucker Diabetic Fatty rat and is independent of glycemic status.
Piercy V; Banner SE; Bhattacharyya A; Parsons AA; Sanger GJ; Smith SA; Bingham S
J Diabetes Complications; 1999; 13(3):163-9. PubMed ID: 10509877
[TBL] [Abstract][Full Text] [Related]
35. Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats.
MacDonald MJ; Tang J; Polonsky KS
Diabetes; 1996 Nov; 45(11):1626-30. PubMed ID: 8866570
[TBL] [Abstract][Full Text] [Related]
36. Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Fürnsinn C; Nowotny P; Brunmair B; Gras F; Roden M; Waldhäusl W; Vierhapper H
Endocrinology; 2002 Jan; 143(1):327. PubMed ID: 11751625
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Livingstone DE; Kenyon CJ; Walker BR
J Endocrinol; 2000 Dec; 167(3):533-9. PubMed ID: 11115781
[TBL] [Abstract][Full Text] [Related]
38. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
Pickavance LC; Brand CL; Wassermann K; Wilding JP
Br J Pharmacol; 2005 Feb; 144(3):308-16. PubMed ID: 15655531
[TBL] [Abstract][Full Text] [Related]
39. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
